Mounjaro

Eli Lilly & Co. (NYSE:LLY) has intensified its fight against counterfeit versions of its popular obesity drug, Zepbound, by initiating additional legal proceedings against companies selling compounded versions of the medication. What Happened: The pharmaceutical company filed several new...

David Ricks, CEO of Eli Lilly and Co (NYSE:LLY), expressed confidence in meeting the lofty revenue expectations set by Bank of America for the company’s upcoming drug launches. What Happened: During an interview on CNBC’s Last Call on Monday, Ricks described the potential market for...

The animated comedy "South Park" is no stranger to taking on hot topics and pop culture figures in its streaming specials. After targeting cryptocurrency and artificial intelligence in recent years, the series now tackles weight-loss drugs. What Happened: "South Park" has tackled many trending...

The return of Roaring Kitty, aka Keith Gill, on social media increased interest in meme stocks and may have kickstarted a short rally to start the trading week. While there are several ETFs that provide exposure to meme stocks, an ETF that previously focused exclusively on meme stocks closed in...

After a blistering performance based on the success of its weight-loss treatments Mounjaro and Zepbound, Eli Lilly & Company (NYSE:LLY) stock has been trading sideways for the last five weeks as the company struggles to keep pace with demand for the drugs. Eli Lilly shares have climbed 162%...

Costco Wholesale Corporation (NASDAQ:COST) has launched a weight management program to help its members in their weight loss journey. The program will provide access to popular weight loss medications from pharmaceutical giants Eli Lilly and Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO). What...

Eli Lilly and Co. (NYSE:LLY) enjoyed meteoric success with its weight loss drugs Mounjaro and Zepbound — the latter already recording stellar sales only three months after launch in December. Recent data showed that, for the first time since launch, Zepbound filled more U.S. prescriptions in a...

The race for new drugs to fight obesity and associated diabetes and cardiovascular diseases heated up on Monday after positive results from trials by Zealand Pharma were published, pushing the Danish company’s shares 30% higher. Zealand Pharma’s survodutide drug showed positive results...

Jim Cramer, the host of CNBC’s “Mad Money,” has issued a warning to investors about the potential impact of weight loss drugs, such as Ozempic and Wegovy, on the food and beverage industry. What Happened: Cramer cautioned investors on Monday about the growing popularity of GLP-1s...

Tesla‘s (NASDAQ:TSLA) standing within the Magnificent Seven is in question. What Happened: The Austin, Texas-based electric vehicle (EV) company now stands at number nine on the list of biggest companies on the S&P 500 index. Therefore, when looking at the top seven stocks on the S&P...

In a recent announcement, Eli Lilly and Co (NYSE:LLY) has projected a significant revenue increase for 2024, driven by the demand for its diabetes and obesity drugs. What Happened: The pharmaceutical giant anticipates a 20% rise in sales, propelling its revenues to over $40 billion, reported the...

Eli Lilly (NYSE:LLY) reports its fourth quarter earnings next week and, as Novo Nordisk (NYSE:NVO) did on Wednesday, is expected to wow investors with earnings and revenue beats thanks, in large part, to the overwhelming success of its diabetes treatments that have become popular weight-loss...

Tesla Inc. (NASDAQ:TSLA) has been surpassed in market value by pharmaceutical giant Eli Lilly (NYSE:LLY), following a 12% single-day plunge in Tesla’s stock. What Happened: Tesla’s fourth-quarter earnings report, which fell short of revenue and profit expectations, triggered a...

Diabetes treatments such as Ozempic and Mounjaro became the blockbuster drugs of 2023 thanks to their popularity as weight-loss remedies. Prices for a month’s supply of these drugs were high then, and in 2024 their manufacturers have raised them higher still. According to data by 46brooklyn...

Congressman Bernie Sanders (I-Vt.) has been known to tussle with public companies over their high prices or anticompetitive behavior, including pharmaceutical companies and their high costs. In his newest battle, Sanders is taking on the growing popularity of weight-loss drugs and diabetes...